Context Therapeutics Inc.
NCM: CNTXLive Quote
About Context Therapeutics Inc.
Healthcare
Biotechnology
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
📊 Fundamental Analysis
Context Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -46.4%, which indicates that capital utilization is currently under pressure.
At a current price of $2.49, CNTX currently sits at the 64th percentile of its 52-week range (Range: $0.49 - $3.62).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$139.66M
Trailing P/E
--
Forward P/E
-5.38
Beta (5Y)
1.83
52W High
$3.62
52W Low
$0.49
Avg Volume
1.33M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App